dgk alpha/zeta inhibitor incb177054
Generic: DGK Alpha/Zeta Inhibitor INCB177054
dgk alpha/zeta inhibitor incb177054: 1 clinical trial tracked.
dgk alpha/zeta inhibitor incb177054 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about dgk alpha/zeta inhibitor incb177054, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
A Phase 1/2, Open-Label, Multicenter Study of INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
Interventionalopen9 targetStarted 2025-06Completion 2026-079 sites · United StatesIncyte Corporation